Recent clinical trials involving anti-PD-1 and anti-PD-L1 monoclonal antibodies (mAbs) have shown efficacy in various malignant tumors, with responses strongly correlated with PD-L1 expression, as assessed by immunochemistry (33–35). This evidence concerns the gene CD274 and cancer.